Nearing phase 3, resTORbio posts new data on infection drug

ResTORbio has shared additional data from a phase 2b trial of RTB101 in patients with respiratory tract infections. The analyses provide further evidence of the effect the TORC1 inhibitor has on the incidence of RTIs and urinary tract infections in high-risk elderly patients.